Husta Bryan C, Raoof Suhail, Erzurum Serpil, Mehta Atul C
Lenox Hill Hospital, Hofstra Northwell School of Medicine, New York, NY.
Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Chest. 2017 Dec;152(6):1296-1305. doi: 10.1016/j.chest.2017.08.013. Epub 2017 Aug 31.
Inhaled corticosteroids (ICSs) have become the mainstay of asthma control. They are also recommended as an add-on therapy to long-acting beta agonists and anticholinergics in moderate to severe COPD with recurrent exacerbations. Ultimately this clinical practice has led to the widespread use of ICSs, which are supported by a more favorable side effect profile than that of systemic steroids.
吸入性糖皮质激素(ICSs)已成为哮喘控制的主要手段。它们还被推荐作为长效β受体激动剂和抗胆碱能药物的附加治疗,用于中度至重度慢性阻塞性肺疾病(COPD)且反复加重的患者。最终,这种临床实践导致了ICSs的广泛使用,与全身用糖皮质激素相比,ICSs具有更有利的副作用谱。